These Were the 5 Best and Worst Performing Mid-Cap Stocks in November 202224/7 Wall Street • 12/13/22
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 AnnuaGlobeNewsWire • 12/07/22
Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A SetbackInvestors Business Daily • 11/28/22
Axsome's stock rallies 15% on promising findings for its experimental Alzheimer's drugMarket Watch • 11/28/22
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer's Disease AgitationGlobeNewsWire • 11/28/22
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/23/22
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.The Motley Fool • 11/18/22